Prevention of Arrhythmia Device Infection Trial (PADIT)
Study Details
Study Description
Brief Summary
The goal of the study is to compare whether a center-wide policy of incremental antibiotic therapy will reduce CIED infection rate compared to a policy of conventional antibiotic prophylaxis in high-risk patients undergoing arrhythmia device procedures. All antibiotics used are approved for use and readily available.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 4 |
Detailed Description
This is a randomized prospective cluster crossover trial to track outcomes of high infection risk patients undergoing arrhythmia device procedures. Centres will be randomized to either conventional antibiotic therapy or incremental antibiotic therapy. Patients will not be randomized. Centres will be randomized to one therapy and then cross over to the next after 6 months. At one year they will randomize again and then cross over for the final time at 18 months. During each treatment period the randomized antibiotic therapy will be used on all centre patients undergoing a device implant procedure.
Ethics approval has been obtained in all sites for waiver of consent with notification of the study (i.e. data collection is taking place to track infection rates). A third of sites obtain consent after the procedure for collection of data (but not for care, since either arm is the standard of care).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Conventional Preoperative Antibiotics: Cefazolin preoperative, vancomycin in penicillin allergic patients. |
Drug: Conventional
Cefazolin preoperative
Other Names:
|
| Experimental: Incremental Preoperative antibiotics (Cefazolin and Vancomycin) Bacitracin pocket wash and 2 days of oral Cefalexin post operative. |
Drug: Incremental
Single dose of Cefazolin and Vancomycin preoperatively, bacitracin wash and cefalexin post operative.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Hospitalization attributed to device infection [Evaluation is one year post patient's procedure]
Secondary Outcome Measures
- 1. Proven device infection not requiring surgical intervention (medically treated device infection). [Up to one year post procedure]
- 2. Any treatment with antibiotics for suspected device infection. [Up to one year post procedure]
- 3. Antibiotic-related adverse events including culture or antigen proven C. difficile infection. [Up to one year post procedure]
- 4. Prolongation of hospitalization due to proven or suspected adverse events from the antibiotic therapy. [Up to one year post procedure]
- Cost benefit analysis [At completion of data collection period]
- 6. Rate of device/lead extraction 12 months post patient's procedure (regardless of the cause). [Up to one year post procedure]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age >= 18 years
-
Received one of the following procedures:
-
A second or subsequent procedure on the arrhythmia device pocket:
ICD, pacemaker, CRT-P, CRT-D generator and/or lead replacement
-
Pocket or lead revision
-
System upgrade (insertion or attempted insertion of leads)
-
New cardiac resynchronization therapy device implant (pacemaker or ICD)
-
Patient is not known to have device infection at the time of the surgery
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Coordinating Centre: Population Health Research Institute | Hamilton | Ontario | Canada | L8L 2X2 |
Sponsors and Collaborators
- Population Health Research Institute
- Canadian Institutes of Health Research (CIHR)
Investigators
- Principal Investigator: Andrew Krahn, MD, University of British Columbia
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PADIT Cluster Crossover Study